Imagine a tiny, dissolvable plug that sits inside the uterus and slowly releases medicine exactly where it is needed. Instead of taking pills that affect the whole body, this device delivers treatment locally and then disappears on its own. It's designed to treat painful uterine conditions without the harsh side effects of systemic drugs.
Current treatments for uterine fibroids and endometriosis often involve systemic drugs with painful side effects or invasive surgeries. There is a significant gap in effective options following the withdrawal of certain appreciated treatments like Esmya.
A biodegradable polymer-based drug delivery platform including 'Womed Leaf' (drug-free for adhesions), 'Fibroid' (for fibroids), and 'ReLeaf' (for endometriosis pain).
If you are a drug developer dealing with the systemic side effects of hormonal treatments — this project developed a biodegradable polymer platform that allows for targeted and controlled release of active ingredients. This enables the delivery of Selective Progesterone Receptor Modulators directly to the uterus.
If you are a device manufacturer dealing with the need for non-permanent intrauterine implants — this project developed a patented copolymer structure that allows for easy insertion and full biodegradability. This removes the need for a second surgical procedure to remove the device.
If you are a clinic operator dealing with uterine adhesions that block fertility — this project developed Womed Leaf, a drug-free device that prevents adhesions and restores fertility. This provides a localized solution to improve patient outcomes in reproductive health.
Based on available project data, specific pricing or cost structures for the devices are not provided.
The project has selected a CDMO in the EU and successfully transferred manufacturing processes, including initial extrusion runs that achieved drug content control and homogeneity.
The platform is based on a unique and patented copolymer structure developed by WOMED.
The project received positive Scientific Advice from a national pharmaceutical Agency in Europe, confirming the suitability of the development plan.
The project period is from 2024-05-01 to 2026-04-30, though specific launch dates are not listed.
The project is led by a single French SME (WOMED), resulting in a 100% industry ratio. This lean structure suggests a highly focused commercial drive, led by a serial MedTech entrepreneur, with a direct pipeline from development to a selected EU-based CDMO for manufacturing.
Contact Gonzague Issenmann at WOMED in Montpellier
Contact us to explore licensing opportunities for the patented copolymer platform.
